As Congress prepares to begin its new term, newly elected lawmakers will convene to tackle issues such as the high cost of drugs. As they prepare to address these policy challenges, a new analysis shows that several key congressional leaders have received major contributions from the pharmaceutical industry.
As Congress prepares to begin its new term, newly elected lawmakers will convene to tackle issues such as the high cost of drugs. As they prepare to address these policy challenges, a new analysis shows that several key congressional leaders have received major contributions from the pharmaceutical industry.
Kaiser Health News (KHN) has reported that several legislators who will wield much of the power in the House in 2019 are among the representatives and senators who have received the most money from the pharmaceutical industry.
Steny Hoyer, D-Maryland; James Clyburn, D-South Carolina; Kevin McCarthy, R-California; and Richard Burr, R-North Carolina, have each received more than $1 million in donations from pharmaceutical companies’ political action committees (PACs) in the past 10 years. Hoyer and Clyburn were recently selected by Democrats to serve as the incoming majority leader and majority whip, respectively. Burr serves on the Senate Committee on Health, Education, Labor, and Pensions.
Over the past decade, says KHN, members of Congress from both parties have accepted approximately $81 million from 68 individual pharma PACs.
Additionally, tax disclosure forms show that the Pharmaceutical Research and Manufacturers of America (PhRMA), a trade group that represents the interests of drug makers including Amgen and Johnson & Johnson, raised revenue by approximately one-fourth in 2016, and spent the collected monies among hundreds of lobbyists, politicians, and patient groups that could further its interests.
The group has attempted to cultivate a bipartisan reputation, but PhRMA may be incented to shift its 2019 lobbying efforts to the Republican-controlled Senate from the Democrat-controlled house. STAT has reported a conversation with a drug industry lobbyist who called the House of Representatives a “dead zone” for industry interests in light of the results of the midterm election and renewed concerns about the high cost of drugs.
Meanwhile, PhRMA has initiated a campaign—called Let’s Talk About Cost—aimed directly at consumers. The campaign addresses such questions as why other countries have lower drug prices, why copay coupons may not count toward deductibles, and who decides what customers pay for their prescription drugs.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.